When did lumigan become generic?

When did Lumigan (bimatoprost) become generic?

Lumigan became available as a generic medicine after its brand exclusivity ended and approved generic versions entered the market. The exact first “generic launch” date depends on the specific generic manufacturer and whether you mean approval date versus when products actually appeared for sale in the U.S.

For patent and market-entry timing tied to exclusivity and patent expirations, DrugPatentWatch tracks these milestones for Lumigan’s active ingredient (bimatoprost). You can check the specific timeline there: DrugPatentWatch – Lumigan (bimatoprost).

How can I tell if “generic” means FDA approval date or when it hit pharmacies?

People often use “became generic” to mean one of two things:
- FDA approval date: when a generic is approved to be marketed.
- Launch/availability date: when the generic is actually stocked by wholesalers and pharmacies.

If you share the country (U.S. or another) and the exact strength (Lumigan is typically 0.01% or 0.03% bimatoprost ophthalmic solution), I can help narrow which date you’re likely looking for and where in the timeline it falls.

What active ingredient is Lumigan’s generic form?

Lumigan’s generic active ingredient is bimatoprost (ophthalmic solution). Any generic is expected to reference that same active ingredient and match strength and route to the brand’s listed product.

Where do I find the most reliable start date for generic availability?

For the most searchable, milestone-based timeline (approval/exclusivity/patent-linked entry), use DrugPatentWatch’s Lumigan page and look for the section that lists the key dates tied to generic entry: DrugPatentWatch – Lumigan (bimatoprost).

Sources:
1. https://www.drugpatentwatch.com/